

Practitioner's Docket No. MPI95-015P1RCPA1DV1M

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of: Phillips, David R., et al  
Application No.: 09/801,089      Group No.: 1644  
Filed: March 08, 2001      Examiner: Ewoldt, Gerald R.  
For: MODULATION OF INTEGRIN-MEDIATED SIGNAL TRANSDUCTION

Commissioner for Patents  
Washington, D.C. 20231

**AMENDMENT TRANSMITTAL**

**RECEIVED**  
MAR 12 2003  
TECH CENTER 1600/2900

1. Transmitted herewith for this application is/are:
  - a. This Amendment Transmittal (2 pages);
  - b. Preliminary Amendment to Figures (2 pages);
  - c. 2 Sheets of Drawings (Figures 2 and 5A-5C);
  - d. Submission of Corrected Sequence Listing (4 pages);
  - e. 12 pages of Corrected Sequence Listing;
  - f. Diskette containing Corrected Sequence Listing;
  - g. Copy of Notice to Comply with Requirements for Patent Applications containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures (1 page);
  - h. Change of Attorney Docket Number (1 page); and
  - i. Return Postcard.

**STATUS**

2. Applicant is other than a small entity.

**CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10\***

I hereby certify that, on the date shown below, this correspondence is being:

**MAILING**

- ☒ deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.

**37 C.F.R. SECTION 1.8(a)**

**37 C.F.R. SECTION 1.10\***

- ☒ with sufficient postage as first class mail.      ☐ as "Express Mail Post Office to Address" Mailing Label No.

**TRANSMISSION**

- ☐ transmitted by facsimile to the Patent and Trademark Office.

*Signature*

Date: 4 March 2003

Simonne Corriveau  
(type or print name of person certifying)

**\*WARNING:** Each paper or fee filed by "Express Mail" **must** have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will **not** be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

The PTO did not receive the following listed item(s) Diskette containing corrected sequence listing

Practitioner's Docket No. MPI95-015P1RCPA1DV1M

**PETITION FOR EXTENSION OF TIME**

3. The proceedings herein are for a patent application and the provisions of 37 C.F.R. 1.136 apply. Applicant petitions for an extension of time under 37 C.F.R. 1.136 (fees: 37 C.F.R. 1.17(a)(1)-(3)) for a N/A month extension:

Fee: \$ 0.00

Extension fee due with this request \$ 0.00

If an additional extension of time is required, please consider this a petition therefor.

**FEE FOR CLAIMS**

4. The fee for claims (37 C.F.R. 1.16(b)-(d)) has been calculated as shown below:

(Col. 1)			(Col. 2)		(Col. 3)		OTHER THAN A SMALL ENTITY		
Claims Remaining After Amendment			Highest No. Previously Paid For		Present Extra		Rate	Addit. Fee	
Total	0	Minus	0	=	0	\$18.00	=	\$0.00	
Indep.	0	Minus	0	=	0	\$84.00	=	\$0.00	
First Presentation of Multiple Dependent Claims			0				\$280.00	=	\$0.00
							Total Addit. Fee		\$0.00

Total additional fee for claims required \$0.00

**FEE PAYMENT**

5. Charge Account No. 501668 the sum of \$0.00 (which includes the \$0.00 extension fee and the \$0.00 additional fee for claims). A duplicate of this transmittal is attached.


**FEE DEFICIENCY**

6. If any additional extension and/or fee is required, charge Account No. 501668.  
If any additional fee for claims is required, charge Account No. 501668.

4 March 2003


MILLENNIUM PHARMACEUTICALS, INC.

By



Tracy M. Sioussat  
Registration No. 50,609  
75 Sidney Street  
Cambridge, MA 02139  
Telephone - 617-374-7679  
Facsimile - 617-551-8820

RECEIVED  
MAR 12 2003  
TECH CENTER 1600/2900



#16  
Gerga

Practitioner's Docket No. MPI95-015P1RCPA1DV1M

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Phillips, David R., et al  
Application No.: 09/801089 Group No.: 1644  
Filed: March 08, 2001 Examiner: Ewoldt, Gerald R.  
For: MODULATION OF INTEGRIN-MEDIATED SIGNAL TRANSDUCTION

Commissioner for Patents  
Washington, DC 20231

RECEIVED  
MAR 12 2003  
TECH CENTER 1600/2900

PRELIMINARY AMENDMENT TO FIGURES

Dear Sir:

In response to the Office communication dated February 7, 2003 (Paper No. 15), requiring sequence identifiers in the Figures, Applicants submit herewith a Preliminary Amendment to the Figures.

IN THE FIGURES

Please replace Figure 2 with the replacement Figure 2 submitted herewith.

Please replace Figure 5 with the replacement Figure 5 submitted herewith.

A copy of the Notice to Comply with Requirements of Patent Applications Containing Nucleotide Sequence and or Amino Acid Sequence Disclosures is enclosed herewith.

---

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10\*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

- ☒ deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.  
37 C.F.R. SECTION 1.8(a) 37 C.F.R. SECTION 1.10\*

- ☒ with sufficient postage as first class mail. ☐ as "Express Mail Post Office to Address" Mailing Label No.

TRANSMISSION

- ☐ transmitted by facsimile to the Patent and Trademark Office.

Signature

Simonne Corriveau

(type or print name of person certifying)

Date: 4 March 2003

**\*WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.